An In-Depth Overview of Interstitial Lung Diseases for Healthcare Professionals

Interstitial lung diseases (ILDs) encompass a heterogeneous group of disorders characterized by inflammation and fibrosis of the pulmonary interstitium. This article provides an overview of ILDs and their clinical relevance.

Etiology and Classification

ILDs can be idiopathic or secondary to systemic diseases, environmental exposures, or drugs. The most common idiopathic ILD is idiopathic pulmonary fibrosis. Other forms include nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, and acute interstitial pneumonia. Secondary ILDs are often associated with connective tissue diseases, hypersensitivity pneumonitis, or occupational lung diseases.

Clinical Presentation and Diagnosis

Patients often present with progressive dyspnea and nonproductive cough. Physical examination may reveal crackles and clubbing. High-resolution computed tomography is the imaging modality of choice, often showing reticular abnormalities, ground-glass opacities, or honeycombing. Pulmonary function tests typically demonstrate a restrictive pattern with reduced diffusion capacity. A definitive diagnosis may require lung biopsy.

Management

Management of ILDs is complex and often requires a multidisciplinary approach. Treatment is generally aimed at controlling inflammation, preventing fibrosis, and managing symptoms. Corticosteroids and immunosuppressive agents are commonly used. In cases of progressive disease, lung transplantation may be considered.

Prognosis

The prognosis of ILDs varies widely, depending on the specific subtype and the individual patient’s response to treatment. Idiopathic pulmonary fibrosis has a particularly poor prognosis, with a median survival of 2-3 years from diagnosis.

In conclusion, interstitial lung diseases are a diverse group of disorders with variable prognosis. A thorough understanding of these conditions is essential in providing optimal care to patients.